KR100378255B1 - Stereoselective preparation method of β-D-mannopyranoside - Google Patents

Stereoselective preparation method of β-D-mannopyranoside Download PDF

Info

Publication number
KR100378255B1
KR100378255B1 KR10-2000-0086281A KR20000086281A KR100378255B1 KR 100378255 B1 KR100378255 B1 KR 100378255B1 KR 20000086281 A KR20000086281 A KR 20000086281A KR 100378255 B1 KR100378255 B1 KR 100378255B1
Authority
KR
South Korea
Prior art keywords
formula
group
hydrogen
benzyl
tri
Prior art date
Application number
KR10-2000-0086281A
Other languages
Korean (ko)
Other versions
KR20020058237A (en
Inventor
정성기
박규환
임현석
Original Assignee
학교법인 포항공과대학교
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 학교법인 포항공과대학교 filed Critical 학교법인 포항공과대학교
Priority to KR10-2000-0086281A priority Critical patent/KR100378255B1/en
Publication of KR20020058237A publication Critical patent/KR20020058237A/en
Application granted granted Critical
Publication of KR100378255B1 publication Critical patent/KR100378255B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)

Abstract

본 발명은 하기 화학식 1로 표시되는 화합물과 저급알코올, 단당류 또는 다당류에 란탄족 촉매를 반응시킴으로써 입체선택적으로 β-D-만노피라노시드(mannopyranoside)를 합성하는 제조방법을 제공한다.The present invention provides a method for synthesizing β-D-mannopyranoside stereoselectively by reacting a lanthanide catalyst with a compound represented by the following formula (1) and a lower alcohol, monosaccharide or polysaccharide.

상기 식에서, R1은 수소, C1내지 C6의 저급알킬기 또는 페닐유도체를 나타내고; R2는 수소, 알킬옥소, 알킬옥시아세틸 또는 알킬옥소아세틸기를 나타내고, 여기서 알킬이란 C1내지 C6의 저급알킬을 의미하며; R3, R4및 R5는 서로 독립적으로 수소 또는 히드록시기의 보호기를 나타내며; n은 0, 1 또는 2의 정수를 나타낸다.Wherein R 1 represents hydrogen, a lower alkyl group of C 1 to C 6 or a phenyl derivative; R 2 represents a hydrogen, alkyloxo, alkyloxyacetyl or alkyloxoacetyl group, wherein alkyl means C 1 to C 6 lower alkyl; R 3 , R 4 and R 5 independently of one another represent a protecting group of hydrogen or a hydroxy group; n represents the integer of 0, 1, or 2.

본 발명에 따르는 제조방법은 란탄족 촉매를 이용함으로써 비교적 간단한 조작으로 β-입체선택성을 높일 수 있다는 장점이 있다.The production method according to the present invention has the advantage that the β-stereoselectivity can be increased by a relatively simple operation by using a lanthanide catalyst.

Description

β-D-만노피라노시드의 입체선택적 제조방법{Stereoselective preparation method of β-D-mannopyranoside}Stereoselective preparation method of β-D-mannopyranoside {Stereoselective preparation method of β-D-mannopyranoside}

본 발명은 β-D-만노피라노시드(mannopyronoside)의 신규한 제조방법에 관한 것으로서, 보다 상세하게는 란탄족 촉매를 사용하여 입체선택적으로 β-D-만노피라노시드를 합성하는 방법에 관한 것이다.The present invention relates to a novel method for preparing β-D-mannopyronoside, and more particularly, to a method for stereoselectively synthesizing β-D-mannopyranoside using a lanthanide catalyst. will be.

최근 생체내에서의 다양한 생리적인 과정에 탄수화물이 관여하고 있다는 것이 알려지면서 탄수화물의 성질이나 역할을 이해하려는 많은 노력이 시도되고 있다. 세포내에서 탄수화물은 당단백질이나 당지질과 같은 형태로 존재하며 세포성장, 면역반응, 염증, 및 바이러스 감염 등에서 중요한 역할을 한다고 알려져 있다. 특히 당단백질은 필수적으로 β-D-만노피라노시드의 잔기를 포함하고 있다. 하지만 생물학적으로 중요한 올리고당의 화학적 합성, 특히 β-D-만노피라노시드를 입체선택적으로 합성하는 것은 매우 어려운 것으로 알려져 있다.Recently, it is known that carbohydrates are involved in various physiological processes in vivo, and many efforts have been made to understand the properties and roles of carbohydrates. Carbohydrates in cells are present in the form of glycoproteins or glycolipids and are known to play an important role in cell growth, immune responses, inflammation, and viral infections. In particular, glycoproteins essentially contain residues of β-D-mannopyranosides. However, chemical synthesis of biologically important oligosaccharides, particularly stereoselectively synthesizing β-D-mannopyranosides, is known to be very difficult.

현재까지 문헌상으로 알려진 입체선택적인 β-D-만노피라노시드 합성을 위한 방법으로는 첫째, 인트라몰레큘라 애글리콘 딜리버리(Intramolecular aglycon delivery, IAD)를 이용하는 방법 (J. Am. Chem. Soc. 1991,113, 9376;J. Am.Chem. Soc. 1996,118, 247;Angew. Chem. Int. Ed. Engl.1994, 33,1765)과 둘째, 당받게를 넣는 시점을 달리함으로써 이중치환반응을 통해 β-형을 합성하는 방법 (J. Org. Chem. 1997,62,1198) 등이 있다.As a method for synthesizing stereoselective β-D-mannopyranoside known to the literature so far, first, the method using intramolecular aglycon delivery (IAD) ( J. Am. Chem. Soc. 1991 , 113 , 9376; J. Am . Chem. Soc. 1996 , 118 , 247; Angew. Chem. Int. Ed. Engl . 1994, 33, 1765). To synthesize β-forms ( J. Org. Chem. 1997 , 62, 1198).

그러나 IAD를 이용하는 방법에서는 적당한 연결가지를 통해 당주게에 당받게를 공유결합으로 연결해야 하는 데, 이 때 여러 단계가 필요하며 다소 불안정한 중간체를 사용해야 한다. 또한 당받게가 이차알코올일 경우 대체로 수율이 낮다. 둘째로 당받게를 넣는 시점을 달리하는 방법에서는 이차알코올에서 선택성이 떨어지고 일부 당주게 외에는 원하는 결과를 얻지 못했다.However, the method using the IAD requires covalent linking of sugar-coated to sugar-coated sugars through a suitable linking branch, which requires several steps and uses a rather unstable intermediate. In addition, the yield is generally low when the sugar acceptor is secondary alcohol. Secondly, in the method of adding sugar acceptor, the selectivity was lowered in the secondary alcohol and the desired result was not obtained except some sugar crab.

따라서, 본 발명이 이루고자 하는 기술적 과제는 상술한 바와 같은 문제점을 해결한 비공유결합을 통한 IAD전략으로 효과적인 β-D-만노피라노시드의 제조방법을 제공하는 것이다.Accordingly, the technical problem to be achieved by the present invention is to provide an effective method for preparing β-D-mannopyranoside as an IAD strategy through a non-covalent bond that solves the above problems.

상기 기술적 과제를 달성하기 위하여, 본 발명은 하기 화학식 1로 표시되는 화합물과 화학식 2로 표시되는 화합물을 화학식 3으로 표시되는 첨가제 존재하에서 반응하여 하기 화학식 4로 표시되는 화합물을 제조하는 것이다.In order to achieve the above technical problem, the present invention is to produce a compound represented by the following formula (4) by reacting the compound represented by the formula (1) and the compound represented by the formula (2) in the presence of an additive represented by the formula (3).

[화학식 1][Formula 1]

상기 식에서, R1은 수소, C1내지 C6의 저급알킬기 또는 페닐유도체를 나타내고; R2는 수소, 알킬옥소, 알킬옥시아세틸 또는 알킬옥소아세틸기를 나타내고, 여기서 알킬이란 C1내지 C6의 저급알킬을 의미하며; R3, R4및 R5는 서로 독립적으로 수소 또는 히드록시기의 보호기를 나타내며; n은 0, 1 또는 2의 정수를 나타낸다.Wherein R 1 represents hydrogen, a lower alkyl group of C 1 to C 6 or a phenyl derivative; R 2 represents a hydrogen, alkyloxo, alkyloxyacetyl or alkyloxoacetyl group, wherein alkyl means C 1 to C 6 lower alkyl; R 3 , R 4 and R 5 independently of one another represent a protecting group of hydrogen or a hydroxy group; n represents the integer of 0, 1, or 2.

ROHROH

상기 식에서 R은 C1내지 C6의 저급알코올, 단당류 또는 다당류를 나타낸다.Wherein R represents C 1 to C 6 lower alcohols, monosaccharides or polysaccharides.

LnXm Ln X m

상기 식에서 Ln은 란탄족 원소이며; X는 F, Cl, Br 혹은 I와 같은 할로겐 원소, 트리플루오로메탄술포네이트(OTf), 히드록시(OH), 니트로(NO3), 산소(O), 아세톡시(CH3CO2), 술포네이트(SO4) 등의 리간드를 나타내며; ℓ은 1 또는 2의 정수; m은 2, 3, 또는 4의 정수를 나타낸다.Ln is a lanthanide element; X is a halogen element such as F, Cl, Br or I, trifluoromethanesulfonate (OTf), hydroxy (OH), nitro (NO 3 ), oxygen (O), acetoxy (CH 3 CO 2 ), Ligands such as sulfonate (SO 4 ); l is an integer of 1 or 2; m represents the integer of 2, 3, or 4.

상기 식에서 R1은 수소, C1내지 C6의 저급알킬기 또는 페닐유도체를 나타내고; R2는 수소, 알킬옥소, 알킬옥시아세틸 또는 알킬옥소아세틸기를 나타내고, 여기서 알킬이란 C1내지 C6의 저급알킬을 의미하며; R3및 R4는 서로 독립적으로 수소 또는 히드록시기의 보호기를 나타내며; R은 상기 화학식 2에서 정의한 바와 같다.In which R 1 represents hydrogen, a lower alkyl group of C 1 to C 6 or a phenyl derivative; R 2 represents a hydrogen, alkyloxo, alkyloxyacetyl or alkyloxoacetyl group, wherein alkyl means C 1 to C 6 lower alkyl; R 3 and R 4 independently of each other represent a protecting group of hydrogen or a hydroxy group; R is as defined in the formula (2).

본 발명에서 다른 특별한 제한이 없는 경우, 각각의 용어는 다음과 같은 의미를 가리킨다.Unless otherwise specified in the present invention, each term refers to the following meaning.

「수소 또는 히드록시의 보호기」란, 예를 들면 메톡시메틸, 메톡시티오메틸, 트리에틸실릴, 트리이소프로필실릴, t-부틸디페닐실릴, t-부틸디메틸실릴, 트리에틸실릴, 트리페닐실릴, 벤질, p-메톡시벤질, t-부톡시메틸, 테트라히드로피라닐, 3,4-디메톡시벤질, o-니트로벤질, 디페닐메틸 및 트리페닐메틸 등을 들 수 있다.The term "protecting group of hydrogen or hydroxy" is, for example, methoxymethyl, methoxythiomethyl, triethylsilyl, triisopropylsilyl, t-butyldiphenylsilyl, t-butyldimethylsilyl, triethylsilyl, triphenyl Silyl, benzyl, p-methoxybenzyl, t-butoxymethyl, tetrahydropyranyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, diphenylmethyl and triphenylmethyl and the like.

「저급알킬」이란, 탄소수 1∼6의 직쇄 또는 분기쇄상의 알킬을 의미하며, 예를 들면, 메틸, 에틸, 프로필, 이소프로필, 부틸, t-부틸 및 페닐 등을 들 수 있다."Lower alkyl" means straight or branched alkyl having 1 to 6 carbon atoms, and examples thereof include methyl, ethyl, propyl, isopropyl, butyl, t-butyl and phenyl.

「저급알코올」이란, 상기 저급알킬이 치환된 알코올을 의미하며, 예를 들면, 메탄올, 에탄올, 프로판올, 이소프로판올, 부탄올 및 페놀 등을 들 수 있다.The term "lower alcohol" means an alcohol substituted with the lower alkyl, and examples thereof include methanol, ethanol, propanol, isopropanol, butanol and phenol.

「란탄족 원소」란 원자번호 57 내지 71의 원소로서, 바람직하게는 Yb, La Sm 및 Eu 등을 들 수 있다.The "lanthanide element" is an element having atomic numbers 57 to 71, and preferably Yb, La Sm, Eu, and the like.

이하 본 발명에 따른 제조방법은 반응식을 통하여 상세히 설명하기로 한다. 이하 반응식에서 R1, R2, R3, R4,R5,R, Ln, X, ℓ, m 및 n은 앞에서 정의한 바와 같다. 상기 기술적 과제를 달성하기 위한 본 발명의 제조방법은 하기 반응식으로 설명할 수 있다.Hereinafter, the preparation method according to the present invention will be described in detail through a reaction scheme. In the following scheme, R 1 , R 2 , R 3 , R 4, R 5, R, Ln, X, L, m and n are as defined above. The production method of the present invention for achieving the above technical problem can be described by the following scheme.

[반응식 1]Scheme 1

먼저 상기 반응식에서 본 발명이 속하는 기술분야에 널리 알려진 통상적 방법으로 제조가 가능한 상기 화학식 1과 화학식 2로 표시되는 화합물에 화학식 3으로 표시되는 란탄족 촉매를 넣어서 반응을 시킴으로써 입체선택적으로 β-D-만노피라노시드가 제조된다. 상기 반응식의 용매로 헥산, 벤젠, 톨루엔, 테트라하이드로퓨란, 디옥산, 디메틸술폭시드, 디메틸포름아미드, 디에틸에테르, 디클로로메탄, 클로로포름 및 아세토니트릴 등이 이용된다.First, in the above reaction scheme, the lanthanide catalyst represented by the formula (3) is added to the compound represented by the formula (1) and the formula (2), which can be prepared by conventional methods well known in the art, to stereo-selectively β-D- Mannopyranosides are prepared. Hexane, benzene, toluene, tetrahydrofuran, dioxane, dimethyl sulfoxide, dimethylformamide, diethyl ether, dichloromethane, chloroform, acetonitrile and the like are used as the solvent of the above reaction scheme.

게다가, 반응의 촉매 또는 첨가제로 N-브로모숙신이미드(NBS), N-요도숙신이미드(NIS), N-클로로숙신이미드(NCS), 트리플루오로메탄술폰산(TfOH), 트리플루오로메탄술폰산 무수물(Tf2O) 등으로 이루어진 그룹에서 선택되는 어느 하나 이상의 촉매를 더 부가할 수 있다. 또한 상기 반응식은 -100 내지 50oC에서 이루어질 수 있으며, 바람직하게는 -80 내지 30oC에서 진행된다.In addition, N-bromosuccinimide (NBS), N-urethosuccinimide (NIS), N-chlorosuccinimide (NCS), trifluoromethanesulfonic acid (TfOH), trifluoro Any one or more catalysts selected from the group consisting of romethanesulfonic anhydride (Tf 2 O) and the like may be further added. In addition, the reaction scheme may be made at -100 to 50 o C, preferably at -80 to 30 o C.

이하 실시예를 통하여 본 발명을 상세히 설명하고자 한다. 하기 실시예에 의해 본 발명의 범위가 제한되지 않는다.Through the following examples will be described the present invention in detail. The scope of the present invention is not limited by the following examples.

[실시예 1]Example 1

메틸 2,3,4-트리-O-벤질-6-O-(3,4,6-트리-O-벤질-D-만노피라노실)-α-D-글루코피라노시드의 제조Preparation of Methyl 2,3,4-tri-O-benzyl-6-O- (3,4,6-tri-O-benzyl-D-mannopyranosyl) -α-D-glucopyranoside

아르곤 기체 조건하에서 3,4,6-트리-O-벤질-1-에틸술피닐-D-만노피라노시드 (30 mg, 60 μmol)와 메틸 2,3,4-트리-O-벤질-α-D-글루코피라노시드 (33.4 mg, 72μmol)를 아세토니트릴 (1 ml)에 녹였다. Eu(OTf)3(36 mg, 60 μmol)와 분자체(molecular sieve) (100 mg)를 넣고 -40oC에서 1시간 교반한 후 포화 소디움티오설페이트 (0.5 ml)로 반응을 중지시켰다. 셀라이트를 이용하여 무기물질을 제거하고, 디클로로메탄으로 유기층을 추출한 후 포화 NaHCO3, 포화 소디움 티오설페이트 및 소금물로 씻어주었다. 유기층은 무수 황산마그네슘으로 건조시키고 감압농축한 후 속성 컬럼크로마토그래피로 메틸 3,4-트리-O-벤질-6-O-(3,4,6-트리-O-벤질-D-만노피라노실)-α-D-글루코피라노시드를 82%의 수율로 얻었다. 이 화합물은 α와 β가 1:4.3의 비율로 얻어졌다. 관찰된 입체선택성은 Eu(OTf)3첨가제를 사용하지 않았을 때와 비교하여 β-아노머(anomer)의 생성이 17.2배 증가된 것에 해당한다.3,4,6-Tri-O-benzyl-1-ethylsulfinyl-D-mannopyranoside (30 mg, 60 μmol) and methyl 2,3,4-tri-O-benzyl-α under argon gas conditions -D-glucopyranoside (33.4 mg, 72 μmol) was dissolved in acetonitrile (1 ml). Eu (OTf) 3 (36 mg, 60 μmol) and molecular sieves (100 mg) were added and stirred at −40 ° C. for 1 hour, followed by quenching with saturated sodium thiosulfate (0.5 ml). The inorganic material was removed using Celite, the organic layer was extracted with dichloromethane and washed with saturated NaHCO 3 , saturated sodium thiosulfate and brine. The organic layer was dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and then methyl 3,4-tri-O-benzyl-6-O- (3,4,6-tri-O-benzyl-D-mannopyranosyl by fast column chromatography. ) -α-D-glucopyranoside was obtained in 82% yield. This compound obtained α and β in a ratio of 1: 4.3. Observed stereoselectivity corresponds to a 17.2-fold increase in the production of β-anomers compared to when no Eu (OTf) 3 additive was used.

α-아노머α-anomer

Rf : 0.17(헥산 : 에틸 아세테이트=2 : 1)Rf: 0.17 (hexane: ethyl acetate = 2: 1)

[α]D 25= +71.2 (c=0.95, CH2Cl2)[α] D 25 = +71.2 (c = 0.95, CH 2 Cl 2 )

1H NMR(CDCl3) : 1 H NMR (CDCl 3 ):

δ 7.40-7.10(m, 30H, aromatic), 5.02-4.40(m, 12H, 6OCH 2 Ph), 4.96(d, J=1.5, 1H, H-1'), 4.60(d, J=3.7, 1H, H-1), 4.03(dd, J=3, 15, 1H, H-2'), 3.99(app t, J=9.4, 1H, H-3), 3.85(dd, J=4.5, 10.0, 1H, H-6a), 3.83(m, 1H, H-3'), 3.82(dd, J=3.5, 10.0, 1H, H-6b), 3.70(m, 3H, H-5, H-4', H-5'), 3.62(dd, J=4.0, 11.0, 1H, H-6a'), 3.55(dd, J=2.0, 11.0, 1H, H-6b'), 3.50(dd, J=3.7, 9.8, H-2), 3.45(app t, J=9.4, 1H, H-4), 3.33(s, 3H, OMe), 2.40(br s, OH)δ 7.40-7.10 (m, 30H, aromatic), 5.02-4.40 (m, 12H, 60 CH 2 Ph), 4.96 (d, J = 1.5, 1H, H-1 ′), 4.60 (d, J = 3.7, 1H, H-1), 4.03 (dd, J = 3, 15, 1H, H-2 '), 3.99 (app t, J = 9.4, 1H, H-3), 3.85 (dd, J = 4.5, 10.0 , 1H, H-6a), 3.83 (m, 1H, H-3 '), 3.82 (dd, J = 3.5, 10.0, 1H, H-6b), 3.70 (m, 3H, H-5, H-4 ', H-5'), 3.62 (dd, J = 4.0, 11.0, 1H, H-6a '), 3.55 (dd, J = 2.0, 11.0, 1H, H-6b'), 3.50 (dd, J = 3.7, 9.8, H-2), 3.45 (app t, J = 9.4, 1H, H-4), 3.33 (s, 3H, OMe), 2.40 (br s, O H )

13C NMR(CDCl3) : 13 C NMR (CDCl 3 ):

δ 138.8-137.8, 128.5-127.5(aromatic), 99.5, 97.8, 82.1, 80.0, 79.9, 77.7, 74.2, 71.2, 69.8, 68.2, 75.8, 75.0, 74.9, 73.4, 73.2, 71.9, 69.8, 65.9, 55.1(OMe)δ 138.8-137.8, 128.5-127.5 (aromatic), 99.5, 97.8, 82.1, 80.0, 79.9, 77.7, 74.2, 71.2, 69.8, 68.2, 75.8, 75.0, 74.9, 73.4, 73.2, 71.9, 69.8, 65.9, 55.1 O Me )

β-아노머β-anomer

Rf : 0.20 (헥산 : 에틸 아세테이트=2 : 1)Rf: 0.20 (hexane: ethyl acetate = 2: 1)

[α]D 25= +34.82 (c=0.35, CH2Cl2)[α] D 25 = +34.82 (c = 0.35, CH 2 Cl 2 )

1H NMR(CDCl3) : 1 H NMR (CDCl 3 ):

δ 7.35-7.15(m, 30H, aromatic), 5.0-4.53(m, 12H, 6OCH 2Ph), 4.51(d, J=3.5, 1H, H-1), 4.10(app s, 1H, H-1'), 4.09(dd, J=1.5, 10.8, 1H, H-6a'),4.00(2t, 1H, J=9.5, H-3, H-4'), 3.91(br s, 1H, H-2'), 3.82(t, J=9.5, 1H, H-4), 3.76(m, 1H, H-5'), 3.73(dd, J=2.0, 10.2, 1H, H-6a), 3.66(dd, J=5.0, 10.2, 1H, H-6b), 3.56(dd, J=5.5, 10.8, H-6b') 3.50(m, 2H, H-2, H-3'), 3.32(m, 1H, H-5), 3.32(s, 3H, OMe), 2.37(br s, 1H, OH) ppmδ 7.35-7.15 (m, 30H, aromatic), 5.0-4.53 (m, 12H, 60 CH 2 Ph), 4.51 (d, J = 3.5, 1H, H-1), 4.10 (app s, 1H, H- 1 '), 4.09 (dd, J = 1.5, 10.8, 1H, H-6a'), 4.00 (2t, 1H, J = 9.5, H-3, H-4 '), 3.91 (br s, 1H, H -2 '), 3.82 (t, J = 9.5, 1H, H-4), 3.76 (m, 1H, H-5'), 3.73 (dd, J = 2.0, 10.2, 1H, H-6a), 3.66 (dd, J = 5.0, 10.2, 1H, H-6b), 3.56 (dd, J = 5.5, 10.8, H-6b ') 3.50 (m, 2H, H-2, H-3'), 3.32 (m , 1H, H-5), 3.32 (s, 3H, OMe), 2.37 (br s, 1H, OH) ppm

13C NMR(CDCl3) : 13 C NMR (CDCl 3 ):

δ 138.8-138.0, 128.5-127.6(aromatic), 100.0, 97.9, 82.2, 81.3, 79.9, 77.6, 75.4, 74.3, 69.8, 68.3, 75.7, 75.2, 74.7, 73.5, 73.4, 71.4, 69.3, 68.18, 55.20 (OMe)δ 138.8-138.0, 128.5-127.6 (aromatic), 100.0, 97.9, 82.2, 81.3, 79.9, 77.6, 75.4, 74.3, 69.8, 68.3, 75.7, 75.2, 74.7, 73.5, 73.4, 71.4, 69.3, 68.18, 55.20 ( O Me )

[실시예 2]Example 2

메틸 3,4,6-트리-O-벤질-β-D-만노피라노시드의 제조Preparation of Methyl 3,4,6-tri-O-benzyl-β-D-mannopyranoside

아르곤 기체 조건하에서 페닐 2-O-(아세톡시아세틸)-3,4,6-트리-O-벤질-1-티오-D-만노피라노시드 (30 mg, 4.8 μmol)을 아세토니트릴 (1 ml)에 녹였다. Yb(OTf)3(10.3 mg, 19.2 μmol)와 분자체 (100 mg)를 넣고 1시간 교반한 뒤 N-브로모숙신이미드 (1.7 mg, 9.6 μmol)를 첨가하였다. 그리고, 당받게인 메탄올 (185μℓ, 4.8 μmol)을 실온에서 천천히 약 1시간에 걸쳐서 적가하였다. 추가로 실온에서 3시간 교반한 후 포화 소디움 티오설페이트 (0.5 ml)로 반응을 중지시켰다. 셀라이트로 여과하여 무기물질을 제거하고 디클로로메탄으로 유기층을 추출한 후 포화 NaHCO3, 포화 소디움 티오설페이트 및 소금물로 씻어주었다. 유기층을 무수 황산마그네슘으로 건조시키고 감압 농축한 후 속성 컬럼크로마토그래피로 메틸 3,4,6-트리-O-벤질-만노피라노시드를 57%의 수율로 얻었다. 이 경우 선택적으로 β-아노머만이 얻어졌으며, Yb(OTf)3첨가제를 사용하지 않을 경우 α-아노머만 생성되는 것과 비교해서 매우 우수한 입체선택성을 보였다.Phenyl 2-O- (acetoxyacetyl) -3,4,6-tri-O-benzyl-1-thio-D-mannopyranoside (30 mg, 4.8 μmol) under argon gas conditions was diluted with acetonitrile (1 ml). Melted). Yb (OTf) 3 (10.3 mg, 19.2 μmol) and molecular sieve (100 mg) were added and stirred for 1 hour, followed by addition of N-bromosuccinimide (1.7 mg, 9.6 μmol). And sugar acceptor methanol (185 µL, 4.8 µmol) was slowly added dropwise at room temperature over about 1 hour. After further stirring at room temperature for 3 hours, the reaction was stopped with saturated sodium thiosulfate (0.5 ml). The inorganic material was removed by filtration through celite, the organic layer was extracted with dichloromethane, and washed with saturated NaHCO 3 , saturated sodium thiosulfate and brine. The organic layer was dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and methyl 3,4,6-tri-O-benzyl-mannopyranoside was obtained by flash column chromatography in a yield of 57%. In this case, only β-anomer was selectively obtained, and when the Yb (OTf) 3 additive was not used, only the α-anomer was produced.

Rf : 0.38 (헥산 : 에틸 아세테이트=1 : 1)Rf: 0.38 (hexane: ethyl acetate = 1: 1)

[α]D 25= -13.0 (c=0.35, CHCl3)[α] D 25 = -13.0 (c = 0.35, CHCl 3 )

1H NMR(CDCl3) : 1 H NMR (CDCl 3 ):

δ 7.35-7.18(m, 15H, 3OCH2 Ph), 4.90-4.52(m, 6H, 3OCH 2Ph), 4.33(d, J=0.8, 1H, H-1), 4.08(app s, 1H, H-2), 3.86(t, J-9.3, 1H, H-4), 3.78(dd, J=2.3, 10.7, 1H, H-6a), 3.72(dd, J=5.0, 8.4, 1H, H-6b), 3.58(app t, J=3.5, 1H, H-3), 3.55(s, 3H, OMe) 3.45(m, 1H, H-5), 2.40(br s, 1H, OH)δ 7.35-7.18 (m, 15H, 3OCH 2 Ph ), 4.90-4.52 (m, 6H, 3O CH 2 Ph), 4.33 (d, J = 0.8, 1H, H-1), 4.08 (app s, 1H, H-2), 3.86 (t, J-9.3, 1H, H-4), 3.78 (dd, J = 2.3, 10.7, 1H, H-6a), 3.72 (dd, J = 5.0, 8.4, 1H, H -6b), 3.58 (app t, J = 3.5, 1H, H-3), 3.55 (s, 3H, O Me ) 3.45 (m, 1H, H-5), 2.40 (br s, 1H, O H )

13C NMR(CDCl3) : 13 C NMR (CDCl 3 ):

δ 138.1, 128.4-127.5(aromatic), 100.7, 81.5, 75.2, 75.1, 74.2, 73.5, 71.4, 69.2, 68.1(3OCH2Ph, ring carbon), 56.9(OMe)δ 138.1, 128.4-127.5 (aromatic), 100.7, 81.5, 75.2, 75.1, 74.2, 73.5, 71.4, 69.2, 68.1 (3O C H 2 Ph, ring carbon), 56.9 (O Me )

본 발명은 실시예를 참고로 설명되었으나 이는 예시적인 것이 불과하며, 본발명이 속하는 기술분야에 통상의 지식을 가진 당업자라면 이로부터 다양한 변경및 균등한 실시가 가능하다는 것이 분명할 것이다. 따라서 본 발명의 진정한 기술적 보호범위는 첨부된 특허청구범위의 기술적 사상에 의하여 정해져야 할 것이다.Although the present invention has been described with reference to the embodiments, these are merely exemplary, and it will be apparent to those skilled in the art that various changes and equivalents can be made therefrom. Therefore, the true technical protection scope of the present invention will be defined by the technical spirit of the appended claims.

상술한 바와 같이 본 발명에 따른 β-D-만노피라노시드의 제조방법은 란탄족 촉매를 이용함으로써 기존의 알려진 방법에서 필요로 하는 당주게 출발물질을 여러 단계를 거쳐 합성할 필요없이 간단하고 입체선택적으로 β-형의 제조가 가능하다는 장점이 있다.As described above, the method for preparing β-D-mannopyranoside according to the present invention is simple and steric, by using a lanthanide catalyst, without the need for synthesizing sugar starting materials required by a known method through several steps. There is an advantage that it is possible to manufacture the β- form selectively.

Claims (5)

하기 화학식 1로 표시되는 화합물과 화학식 2로 표시되는 화합물을 화학식 3으로 표시되는 첨가제 존재하에서 반응하여 화학식 4로 표시되는 화합물의 제조방법.A method for preparing a compound represented by Formula 4 by reacting the compound represented by Formula 1 with the compound represented by Formula 2 in the presence of an additive represented by Formula 3. [화학식 1][Formula 1] [화학식 2][Formula 2] ROHROH [화학식 3][Formula 3] LnXm Ln X m [화학식 4][Formula 4] 상기 식들에서, R1은 수소, C1내지 C6의 저급알킬기 또는 페닐유도체를 나타내고; R2는 수소, 알킬옥소, 알킬옥시아세틸 또는 알킬옥소아세틸기를 나타내고, 여기서 알킬이란 C1내지 C6의 저급알킬을 의미하며; R3, R4및 R5는 서로 독립적으로 수소 또는 히드록시기의 보호기를 나타내며; ROH는 C1내지 C6의 저급알코올, 단당류 또는 다당류를 나타내고; Ln은 란탄족 원소를 나타내며; X는 할로겐 원소, 트리플루오로메탄술포네이트(OTf), 히드록시(OH), 니트로(NO3), 산소(O), 아세톡시(CH3CO2), 술포네이트(SO4) 등의 리간드를 나타내며; ℓ은 1 또는 2의 정수; m은 2, 3, 또는 4의 정수; n은 0, 1 또는 2의 정수를 나타낸다.In the above formulas, R 1 represents hydrogen, C 1 to C 6 lower alkyl group or phenyl derivative; R 2 represents a hydrogen, alkyloxo, alkyloxyacetyl or alkyloxoacetyl group, wherein alkyl means C 1 to C 6 lower alkyl; R 3 , R 4 and R 5 independently of one another represent a protecting group of hydrogen or a hydroxy group; ROH represents C 1 to C 6 lower alcohols, monosaccharides or polysaccharides; Ln represents a lanthanide element; X is a ligand such as a halogen element, trifluoromethanesulfonate (OTf), hydroxy (OH), nitro (NO 3 ), oxygen (O), acetoxy (CH 3 CO 2 ), sulfonate (SO 4 ) Represents; l is an integer of 1 or 2; m is an integer of 2, 3, or 4; n represents the integer of 0, 1, or 2. 제 1항에 있어서, 상기 화학식 4의 화합물이 2,3,4-트리-O-벤질-6-O-(3,4,6-트리-O-벤질-D-만노피라노실)-α-D-글루코피라노시드인 것을 특징으로 하는 제조방법.The compound of formula 1, wherein the compound of formula 4 is 2,3,4-tri-O-benzyl-6-O- (3,4,6-tri-O-benzyl-D-mannopyranosyl) D-glucopyranoside production method. 제 1항에 있어서, 상기 화학식 4의 화합물이 메틸 3,4,6-트리-O-벤질-β-D-만노피라노시드인 것을 특징으로 하는 제조방법.The method of claim 1, wherein the compound of formula 4 is methyl 3,4,6-tri-O-benzyl-β-D-mannopyranoside. 제 1항에 있어서, 반응성을 향상시키기 위한 첨가제 및 활성제로서 N-브로모숙신이미드(NBS), N-요도숙신이미드(NIS), N-클로로숙신이미드(NCS), 트리플릭산(TfOH), 트리플릭산 무수물(Tf2O) 등으로 이루어진 군에서 선택된 어느 하나 이상을 사용하는 것을 특징으로 하는 제조방법.The method according to claim 1, wherein N-bromosuccinimide (NBS), N-urisuccinimide (NIS), N-chlorosuccinimide (NCS), triflic acid ( TfOH), triflic acid anhydride (Tf 2 O) and the like, any one or more selected from the group consisting of. 제 1항에 있어서, 헥산, 벤젠, 톨루엔, 테트라하이드로퓨란, 디옥산, 디메틸술폭시드, 디메틸포름아미드, 디에틸에테르, 디클로로메탄, 클로로포름 및 아세토니트릴 등으로 이루어진 군에서 선택된 하나 이상을 용매로 사용하는 것을 특징으로 하는 제조방법.The solvent according to claim 1, wherein at least one selected from the group consisting of hexane, benzene, toluene, tetrahydrofuran, dioxane, dimethyl sulfoxide, dimethylformamide, diethyl ether, dichloromethane, chloroform and acetonitrile is used as a solvent. Manufacturing method characterized in that.
KR10-2000-0086281A 2000-12-29 2000-12-29 Stereoselective preparation method of β-D-mannopyranoside KR100378255B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR10-2000-0086281A KR100378255B1 (en) 2000-12-29 2000-12-29 Stereoselective preparation method of β-D-mannopyranoside

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2000-0086281A KR100378255B1 (en) 2000-12-29 2000-12-29 Stereoselective preparation method of β-D-mannopyranoside

Publications (2)

Publication Number Publication Date
KR20020058237A KR20020058237A (en) 2002-07-12
KR100378255B1 true KR100378255B1 (en) 2003-03-29

Family

ID=27689340

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2000-0086281A KR100378255B1 (en) 2000-12-29 2000-12-29 Stereoselective preparation method of β-D-mannopyranoside

Country Status (1)

Country Link
KR (1) KR100378255B1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09249687A (en) * 1996-03-09 1997-09-22 Noguchi Kenkyusho 6-0-mannopyranosyl-1,5 gluconolactone, its production and intermediate therefor
JPH09249681A (en) * 1996-03-09 1997-09-22 Noguchi Kenkyusho 6-0-(2-acetamidoethylphosphonyl)-d-mannopyranoside derivative and its production
JPH10204096A (en) * 1997-01-27 1998-08-04 Kanebo Ltd Mannopyranosyl derivative, agent containing the derivative as active component and its production intermediate
KR0151799B1 (en) * 1992-06-30 1998-10-15 박태준 D-manno pyranos compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0151799B1 (en) * 1992-06-30 1998-10-15 박태준 D-manno pyranos compounds
JPH09249687A (en) * 1996-03-09 1997-09-22 Noguchi Kenkyusho 6-0-mannopyranosyl-1,5 gluconolactone, its production and intermediate therefor
JPH09249681A (en) * 1996-03-09 1997-09-22 Noguchi Kenkyusho 6-0-(2-acetamidoethylphosphonyl)-d-mannopyranoside derivative and its production
JPH10204096A (en) * 1997-01-27 1998-08-04 Kanebo Ltd Mannopyranosyl derivative, agent containing the derivative as active component and its production intermediate

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ann. RCNBMA Vol 8.70-76, 1999 *
Carbohydr Res 1991 Oct 14;219:51-69 *
Carbohydr Res. 1990 Oct 15;207(1):57-69.] *

Also Published As

Publication number Publication date
KR20020058237A (en) 2002-07-12

Similar Documents

Publication Publication Date Title
US5861492A (en) Solution and solid-phase formation of glycosidic linkages
CA2315209C (en) Process for the preparation of 6-o-methyl erythromycin a using 9-hydroxy erythromycin derivatives
EP0242736B1 (en) Sialosylceramides and production method thereof
HU193157B (en) Process for preparing 4"-epi-erythromycin a and derivatives thereof
CN113527388A (en) Stereoselective synthesis method of beta-2-deoxy sugar, 2-deoxy-2-azido sugar and glucoside bond
HU205133B (en) Process for producing epipodophyllotoxin altroside derivatives and pharmaceutical compositions comprising same
US5519122A (en) 16-membered macrolide derivatives and process for producing the same
KR100378255B1 (en) Stereoselective preparation method of β-D-mannopyranoside
US5635612A (en) Method of forming multiple glycosidic linkages in a single step
Lundt et al. Ethylation of thiolaevoglucosan to a crystalline sulfonium salt and reaction of the latter with nucleophile
EP0882733B1 (en) Acylating agent and a method of producing thereof
JP2540400B2 (en) Method for producing L-talopyranoside derivative
Lubineau et al. Synthesis of aryl d-gluco-and d-galacto-pyranosides and 1-O-acyl-d-gluco-and-d-gluco-pyranoses exploiting the mitsunobu reaction. Influence of the pKa of the acid on the stereoselectivity of the reaction
KR100966986B1 (en) Process for producing 1,2-trans-glycoside compound
US5319077A (en) Process for the preparation of sugar epitopes
US6376662B1 (en) Method for synthesizing C-glycosides of ulosonic acids
JP4162739B2 (en) Process for producing glycoside derivatives
KR920000620B1 (en) New anthracycline glycosides derivatives
CN1066455C (en) New secomacrolides from class of erythromycins and process for their preparation
CN115433243A (en) Method for synthesizing 1,1' -thiodisaccharide with high stereoselectivity by organic catalysis
CN116715704A (en) Chondroitin oligosaccharide based on click chemistry and preparation method thereof
JPH08246179A (en) Production of glycosyl compound
JP3553989B2 (en) Novel glycosyl donor and method for producing glycoside compound using the same
Sarkar et al. Revised synthesis of the pentasaccharide related to the repeating unit of the O-antigen from Shigella dysenteriae type-4 in the form of its methyl ester 2-(trimethylsilyl) ethyl glycoside
JP2004099575A (en) New d-galactosamine derivative and synthetic method for mucin core 2 class by using the same

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060315

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee